HopSo-VL Tablet 400 mg + 100 mg is a fixed-dose combination antiviral therapy containing Sofosbuvir 400 mg and Velpatasvir 100 mg, designed for the treatment of chronic hepatitis C virus (HCV) infection. This combination represents a pangenotypic, interferon-free treatment, effective against all major HCV genotypes (1–6), providing a simplified and highly effective therapy option.

• Sofosbuvir is a nucleotide analog NS5B polymerase inhibitor that blocks viral RNA replication.

• Velpatasvir is an NS5A inhibitor that interferes with viral replication and assembly.

Together, Sofosbuvir and Velpatasvir act synergistically to halt viral replication, reduce viral load, and restore liver function, offering a high cure rate with minimal side effects. The tablet is intended for once-daily oral administration, improving treatment adherence and convenience.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Indications

HopSo-VL Tablet 400 mg + 100 mg is indicated for:

• Chronic hepatitis C infection in adults and adolescents (≥12 years)

• All HCV genotypes (1–6), including difficult-to-treat variants

• Patients with compensated cirrhosis or advanced fibrosis, under medical supervision

• Treatment-naïve and previously treated patients, including those with prior interferon or DAA therapy

• Patients co-infected with HIV, under specialist guidance

• Interferon-free therapy, reducing side effects compared to older regimens

Clinical studies show that this combination achieves sustained virologic response (SVR) rates exceeding 95%, effectively curing most patients.

Dosage and Administration

• Adults and adolescents (≥12 years): One tablet daily, with or without food, as prescribed by a healthcare professional

• Standard treatment duration is 12 weeks, although some patients may require adjustment based on liver status or prior treatment history

• Do not crush, chew, or split the tablet; swallow it whole with water

• Consistent daily use is crucial to prevent viral resistance and maximize treatment efficacy

• Concomitant medications, particularly acid-reducing drugs, should be discussed with a healthcare provider, as they may reduce Velpatasvir absorption

Benefits

• Pangenotypic activity makes it effective against all major HCV genotypes

• Dual antiviral mechanism enhances viral suppression and prevents replication

• Once-daily oral regimen simplifies therapy and improves adherence

• Interferon-free, significantly reducing common adverse effects such as fatigue, depression, and flu-like symptoms

• Improves liver function, reduces inflammation, and lowers the risk of cirrhosis or liver cancer

• Suitable for both treatment-naïve and experienced patients, including those with compensated cirrhosis

Side Effects

HopSo-VL Tablet is generally well tolerated. Common side effects may include:

• Fatigue, headache, nausea, and insomnia

• Rare gastrointestinal disturbances such as diarrhea or mild abdominal discomfort

• Allergic reactions are uncommon but may include rash, itching, or swelling

• When used with ribavirin, mild anemia or irritability may occur

Patients should report any persistent or severe symptoms to their healthcare provider immediately.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Precautions

• Use caution in patients with decompensated liver disease, under specialist supervision

• Pregnant or breastfeeding women should use only under medical guidance

• Inform the healthcare provider of all medications to avoid potential drug interactions

• Avoid alcohol and hepatotoxic drugs during treatment

• Regular monitoring of liver function tests and HCV RNA levels is recommended

Storage

Store in a cool, dry place below 30°C, protected from sunlight and moisture. Keep out of reach of children.

HopSo-VL Tablet 400 mg + 100 mg (Sofosbuvir + Velpatasvir) is a highly effective, pangenotypic, and convenient antiviral therapy that provides safe and targeted treatment, achieving high cure rates and promoting liver health under proper medical supervision.